Vivint Solar Stock Jumps on Goldman's Bullish Outlook

VSLR stock has been more volatile than usual in recent months

by Karee Venema

Published on Mar 14, 2019 at 10:13 AM
Updated on Mar 14, 2019 at 10:30 AM

The shares of Vivint Solar Inc (NYSE:VSLR) are up 4% to trade at $5.21, after Goldman Sachs took a bullish stance to the alternative energy sector. The brokerage firm said it anticipates " lower costs for solar and favorable policy support ... to drive meaningful upside to the market," and forecast year-over-year utility-sector solar installation growth of 12% in 2019, and another 10% in 2020. Further, Goldman said it expects "some of the strongest growth to materialize in key regions such as the U.S., Europe, and the Middle East."

It's been a volatile stretch for VSLR stock, per its annual-high 120-day historical volatility of 66.1%. Looking closer, the shares hit a two-year high of $7.44 on Nov. 28, before retreating all the way back to a nine-month low of $3.55 on Dec. 27. Vivint Solar went on to retrace roughly 50% of this sell-off, before pulling back to find support at its 40-day moving average. Today's trendline has the stock back above its 200-day trendline, which has served as a magnet for the shares in recent sessions.

Most analysts are upbeat toward the solar stock, with 80% in coverage maintaining a "strong buy" rating, and not a single "sell" on the books. Plus, the average 12-month price target of $8.15 is a 56.4% premium to current trading levels.

Short sellers, meanwhile, have been in cover-mode recently. Short interest fell 5.2% in the latest two-week reporting period to 6.44 million shares. These bearish bets still account for 15.3% of VSLR stock's available float, or 11.1 times the equity's average daily pace of trading.


a schaeffer's exclusive

5 HOT STOCK PICKS

Heat up your summer trading with this FREE insider report!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.
3 Drug Stocks Seeing Unusual Options Trading Today
The FDA approved Sesen's request to move manufacturing for its bladder cancer drug
BofA-Merrill Lynch: Buy This Shoe Stock Before Earnings
The brokerage firm thinks the retailer can rally another 26%
This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.